BRAF and neoplasm: Determining the mutation status of the tumor could be useful with regards to therapeutic consequences, since several studies have shown an improved progression-free survival and overall survival, in patients with metastasized cutaneous melanoma harboring a BRAF mutation, using BRAF inhibitors [30].